Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed.

The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.

The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.

The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.

A citrine pleurotus (Pleurotus citrinopileatus) polysaccharide and application thereof are provided, which relate to the field of natural product development and utilization. The citrine pleurotus polysaccharide includes xylose, glucose, galactose, glucuronic acid, fucose, fructose and arabinose. The citrine pleurotus polysaccharide can be applied in preparing drugs for treating sarcopenia caused by cancers. It is demonstrated that the polysaccharide of citrine pleurotus may increase a body weight and a spleen weight, restore morphology, number and density of muscle fibers, reduce inflammatory response and decrease expressions of signature proteins of Atrogin-1 and MuRF-1 for sarcopenia, and alleviate symptoms of tumor-induced sarcopenia in mice with colon cancer cachexia. New effects of polysaccharides of citrine pleurotus are discovered, which provides new ideas for exploitating the citrine pleurotus and treating the sarcopenia caused by cancers.

A citrine pleurotus (Pleurotus citrinopileatus) polysaccharide and application thereof are provided, which relate to the field of natural product development and utilization. The citrine pleurotus polysaccharide includes xylose, glucose, galactose, glucuronic acid, fucose, fructose and arabinose. The citrine pleurotus polysaccharide can be applied in preparing drugs for treating sarcopenia caused by cancers. It is demonstrated that the polysaccharide of citrine pleurotus may increase a body weight and a spleen weight, restore morphology, number and density of muscle fibers, reduce inflammatory response and decrease expressions of signature proteins of Atrogin-1 and MuRF-1 for sarcopenia, and alleviate symptoms of tumor-induced sarcopenia in mice with colon cancer cachexia. New effects of polysaccharides of citrine pleurotus are discovered, which provides new ideas for exploitating the citrine pleurotus and treating the sarcopenia caused by cancers.

A composition for treating, ameliorating, or preventing an infection in a mammalian urinary tract is provided. The composition comprises a monosaccharide comprising a D-mannose, an oligosaccharide comprising an isolated human milk oligosaccharide (HMO), a flavonoid comprising an A-type proanthocyanidin, quercetin, a vitamin comprising ascorbic acid, a green tea extract, and optionally a triterpenoid comprising ursolic acid. A method of treating, ameliorating, or preventing an infection in a urinary tract of a mammal is also provided, and comprises administering the composition to the mammal.

A composition for treating, ameliorating, or preventing an infection in a mammalian urinary tract is provided. The composition comprises a monosaccharide comprising a D-mannose, an oligosaccharide comprising an isolated human milk oligosaccharide (HMO), a flavonoid comprising an A-type proanthocyanidin, quercetin, a vitamin comprising ascorbic acid, a green tea extract, and optionally a triterpenoid comprising ursolic acid. A method of treating, ameliorating, or preventing an infection in a urinary tract of a mammal is also provided, and comprises administering the composition to the mammal.

A composition for treating, ameliorating, or preventing an infection in a mammalian urinary tract is provided. The composition comprises a monosaccharide comprising a D-mannose, an oligosaccharide comprising an isolated human milk oligosaccharide (HMO), a flavonoid comprising an A-type proanthocyanidin, quercetin, a vitamin comprising ascorbic acid, a green tea extract, and optionally a triterpenoid comprising ursolic acid. A method of treating, ameliorating, or preventing an infection in a urinary tract of a mammal is also provided, and comprises administering the composition to the mammal.